grant application & funding approval from Hoxworth Blood Center to the Heimlich Institute

8/4/2019 grant application & funding approval from Hoxworth Blood Center to the Heimlich Institute

1/62

Inscho, Scott (inschots)

From: Inscho, Scott (inschots)Sent: Friday, October 16, 2009 9:53 AMTo: 'pheimlich@cinci,rr,com'Cc: 'Joshua B. Bolinger'; Sacher, Ronald (sacherra)Subject: Heimlich Institute Grant RequestsAttachments: cgf_program_request_budget(2) (2)TL.xlsx; HEIMLICH-CANCELAS-CX43 GRANT

PROPOSAL FINALd .docx; Hoxworth - Heimlich application form BONE MARROW

TRANSPLANT2.docx;cgf_program_request_budget(1)Connexin-43.xlsx;cgf_budget_fiscal_year(1).xlsx; cgf_stmt_rev_exp{1) .xlsx; IRS Exempt Letter UCFoundation.pdf; Trustee List04-27-09.docx; CAB member list 8-09 .docx

Dear Mr. Heimlich.,

We are pleased to submit two grant proposals to the Heimlich Institute. Please review these

and let us know if you have any questions. We appreciate this opportunity. Please let us know

when the Board meeting will take place. Thanks, Scott

T. Scott Inscho

Division Director, Finance

Hoxworth Blood Center

3130 Highland Avenue

Room 4062

Cincinnati, Ohio 45267-0055

phone: 513-558-1243

fax: 513-558-1253

Hoxworth Blood Center

Our Donors Save Lives I

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use

of the intended recipient(s) and may contain confidential and privileged information. Any

unauthorized review, use, disclosure or distribution is prohibited. If you are not theintended recipient, please contact the sender by reply e-mail and destroy all copies of the

original message.

l


2/62

Ohio Common Grant Form

PROGRAM REQUEST BUDGET Cellular Immunotherapy Project

Name of Organization: Hoxworth Blood Center

Time Period (mm/dd/yy to mm/dd/yy): 12/01/09 to 11/30/12

(items typical for running a program)

REVENUE/SUPPORT Budqet

Corporate grants

Foundation grants $313,110

Govt. grants/contracts/per diem (describe in narrative)

Contributions

Affiliate orgs./non-govt. contracts (describe in narrative)

Federated campaigns (describe in narrative)

Membership dues

Special events, fundraisers

Sponsorships

Admissions

Sales, rent

Revenue, tuition

Endowment funds

Interest, dividends, non-endowments investments

Other (describe in narrative if more than 20% of total revenues)

Total Revenue/Support $313,110


3/62


PROGRAM REQUEST BUDGET Cellular immunotherapy Project

Name of Organization: Hc/vvo-th 3!oa-.i CeV.er

Time Period {mm/dd/yy to mm/dd/yy): 12 C1."-i- l j 1 ' ?C"

EXPENSES Budqet

Salaries $128,910

Employee benefits, taxes

Affiliate orgs. or contracts (describe in narrative)

Professional fees

Equipment, supplies, materials $172,700

Telephone, utilities

Postage, mailing

Occupancy

Insurance

Training, staff development $7,500

Travel

Conferences $4,000

Evaluations

Other (describe in narrative if more than 20% of total expenses)

TOTAL EXPENSES $313,110

Revenue less Expenses $0

If expenses exceed revenues/support by more than 10%, please explain how differencewill be offset. Please attach narrative if you have expenses, revenues or a deficit that

require more information or if you believe additional explanation is warranted for anyitem.


4/62

^ / S J Ohio Common Grant Form 1A S GRANT APPLICATION SHORT FORM

Dear Nonprofit Colleague,

The GrantApplicationShort Form was developed by a task force ofOhio Grantmakers Forum(OGF) as part of a series of statewide common grant forms. OGF and its members created thisform to make the grantseeking process simpler and more efficient for nonprofits.

Please keep in mind that every funder has different guidelines and priorities, as well as differentdeadlines and timetables. Before submitting this application to a potential grantmaker, it isvery important that you check to see whether your project or program matches theirpublished interests. Any funder that has agreed to accept this form may request additionalinformation as needed. In addition, a funder may require that a grantseeker complete the longerGrant Application. Please check with the funder which form they require.

STRATEGIES FOR SUCCESSFUL GRANTSEEKING

1. Do your research to determine whether the foundations' and corporations' goals andobjectives for grantmaking are consistent with your type of grant request.

2. After you do the research, find out the preferred method of contact for the grantmaker, andcontact the grantmaker to secure their specific grantmaking guidelines. Many flindersgenerally like to have initial contact with you before receiving a written proposal.

3. Complete the letter of inquiry for those funders that require that form BEFORE completingthis common application. The mnder's guidelines will state whether a letter of inquiry isrequired or not.

4. Include a cover letter with each proposal that introduces your organization and yourproposal, and makes a strategic link between your proposal and the mnder's mission andgrantmaking interests.

5. Provide responses that are typed, single-spaced, single-sided and use a 12-point type.6. Answer all the questions in each section, UNLESS otherwise indicated by the funder. Atthe mnder's discretion, you may answer the questions individually or group then into onenarrative for each section (for Sections Two to Six).

7. Submit the number of copies each grantmaker requests according to their guidelines.8. Do not include any materials other than those specifically requested at this time.9. If completing an online application, you are strongly encouraged to fill out and save the

Microsoft Word version of the common grant applicationshort form on your computer.Then proceed to cut and paste the requested information into the funder's online application.

RESOURCES

Call, write or check the website of each grantmaker to obtain a copy of their fundingguidelines.

Use OGF's Guide to Ohio Grantmakers and other directories listing foundations' interestsand processes.

Visit a Foundation Center Cooperative Collection which can be located atwww.fdncenter.org/cleveland.

Updated; 8/1/2008
http://www.fdncenter.org/clevelandhttp://www.fdncenter.org/clevelandhttp://www.fdncenter.org/cleveland


5/62

fif SJ Ohio Common Grant Form 2^ \ 5 ] GRANT APPLICATION SHORT FORM

To download this form, visit OGF's website at:www.ohiograntmakers.org

SECTION ONE

Funder to which this application isdirected

The Heimlich Institute

Date of Application 10/16/09

ORGANIZATION INFORMATION

Applicant Organization (Full Legal Name) The University of Cincinnati Foundation

Doing Business As

Previous Name, if changed

IRS letter date January 24, 1977

Tax Exempt ID # (EIN) 31-0896555

Name of Executive DirectorMichael Carroll - University of CincinnatiFoundationRonald A. Sacher, MD - Hoxworth

Name of Fiscal Sponsor (if applicable)

CONTACT INFORMATION

Proposal Contact Name Scott Inscho

Title Division Director, FinancePhone 513-558-1243

Fax 513-558-1253

E-mail [email protected]

Street Address Hoxworth Blood Center, 3130 Highland Ave

City Cincinnati

State OH

Zip Code 45267-0055Organization Website www.hoxworth.org

Mailing Address {if different than streetaddress)

City

State

Updated: 8/1/2008
http://www.ohiograntmakers.org/mailto:[email protected]://www.hoxworth.org/http://www.hoxworth.org/mailto:[email protected]://www.ohiograntmakers.org/


6/62

fjfij Ohio Common Grant Form 3J l f i j GRANT APPLICATION SHORT FORM

Zip Code

Updated: 8/1/2008


7/62

83Ohio Common Grant FormGRANT APPLICATION SHORT FORM

ORGANIZATION FINANCIAL INFORMATION

Organization's Budgeted Expenses forCurrent Year (give fiscal year end mm/dd/yy)

$40,135,674 6/30/10

Endowment Size (market value asof fiscalyear mm/dd/yy)

$0

Organization's Major Funding Sourcesby percentage (e.g., United Way, localcommunity foundation, county board of health,etc.)

Revenues from sales of blood products andservices.

ORGANIZATION'S AFFILIATION

United Way X Other specify: University of Cincinnati [X] Chapter of national orregional organization

specify: AABB, America's Blood Centers, Blood Centers of America

REQUEST DATA

Program/Project Title R edac ted in bone marrow failure afterProgram/Project Title cancer-related chemotherapy

Total Budget for this Program/Project $1,500,000

Amount of this request $344,890

Grant Duration (e.g., one-year, two-year,etc.)

3 years

Anticipated Project Start Date December 1,2009

Community/Counties served by thisProgram/Project

Cincinnati, Hamilton County, OH

Total Number of people to be served during

grant period

NA-Developmental

Brief demographic description of populationserved by this Program/Project

Animal model research - No clinical data areneeded. Major implications for human health.

TYPE OF REQUEST (checkall that apply)

Capital Technical assistance X Operating Endowment

X Program/Project Start-up Qother _ specify:

SIGNATURES (both are required unless otherwise specified by funder)

Signature of Executive Director

Signature of Board President

- Z:J

Updated: a/1/2008


8/62

Ohio Common Grant Form 5GRANT APPLICATION SHORT FORM

In general, the following narratives, which include Sections Two through Six, should not exceedfive pages in total (please confirm any page limits with each foundation to which you aresubmitting the application). Responses should be typed, single-spaced, single-sided and use a12-point type. At the funder's discretion, you may answer questions individually or group theminto one narrative for these sections (Section Two to Section Six).

SECTION TWO - ORGANIZATIONAL BACKGROUND

1) Brief summary of organization's history and statement of organization's mission

Hoxworth Blood Center is one of the oldest community blood centers in the country. Founded inDecember, 1938 by Cincinnati surgeon Paul I. Hoxworth, MD, the blood bank was firstestablished as a not-for-profit organization operating under the auspices of the Cincinnati and

Hamilton County Chapter of the American Red Cross. As World War II began to draw to aclose, the American Red Cross turned the blood bank over to the University of Cincinnati (UC)College of Medicine and it became known as the UC Blood Transfusion Service. The bloodcenter was renamed for its founder in 1973.

Today, more than 250 employees staff Hoxworth's main facility, nine neighborhood donorcenters, and its mobile collection operations. The blood center distributes more than 200,000blood components annually. Hoxworth serves 32 hospitals and medical centers in a 17-countyregion in Ohio, Kentucky and Indiana, and relies on 350 donors daily to meet the needs oftri-state patients. Hoxworth is the tri-state's only blood center.

Our mission is to enhance the well being of patients in our service area by assuring a reliable andeconomical supply of the safest possible blood, by providing innovative hemotherapy services,and by promoting research and education programs in transfusion medicine.

2) Brief description of current programs/proj ects and activities

Hoxworth Blood Center, University of Cincinnati Academic Health Center, is the only bloodcenter for the greater Cincinnati area. Hoxworth is a component of the University of Cincinnatiand is therefore governed by the University of Cincinnati Board of Trustees. Hoxworth doeshave a Community Advisory Board and a Medical and Technical Advisory Committee, hiaddition to providing blood products to the tri-state's 32 hospitals, Hoxworth also processesprogenitor cells for transplants, provides tissue-typing services and has a strong transfusionmedicine research program. Hoxworth also has graduate and post-graduate programs intransfusion medicine. Hoxworth is licensed and regulated by the U.S. Food and DrugAdministration and accredited by the AABB (formerly known as the American Association ofBlood Banks), the American Society for Histocompatibility and Iinmunogenetics, and theFoundation for the Accreditation of Cell Therapies. Hoxworth is also a member of America'sBlood Centers and Blood Centers of America.

Updated: 8/1/2008

m


9/62

Fi f S j Ohio Com mon Grant Form 6\jS\ GRANT APPLICATION SHORT FORM

3) Evidence of organization's overall effectiveness based on achievement of specificorganizational of program goals

Major achievements in the past two years include:-Hoxworth collected over 178,000 red blood cell units.

-Hoxworth received a $15,000 gift from the Bernard and Pamela Barbash Foundation towarda new Hoxworth bloodmobile.-Hoxworth started to collect blood from 16 year-old donors on August 27, 2008. We havecollected 2,436 units from these donors.-Dr. Jose Cancelas, Division Director of Research, was awarded the 2008 David B. Pall prizefor innovative research in transfusion medicine. This award recognizes a scientist whoseoriginal research resulted in an important contribution to the body of scientific knowledge.The recipient is selected by the National Blood Foundation Scientific Grants ReviewCommittee.-Hoxworth began providing a new service, photopheresis therapy, where instrumentation andmedication are used to treat chronic graft vs. host disease, cutaneous T cell lymphoma and

heart-transplant rejection.-Hoxworth implemented a new branding initiative that resulted in a new logo and brandingfor Hoxworth.-Hoxworth welcomed the West Chester Medical Center to our family of customers. This newhospital opened in early May 2009.-Hoxworth's Cell Therapy Division has been working with the UC Department of Surgery toprovide processing and quality assurance support for their autologous pancreatic islet cellisolation procedure.

4) Description of population and geographic region (community/county) served by thisorganization

Counties served by Hoxworth Blood Center:Ohio: Adams, Butler, Brown, Clermont, Hamilton, Highland, Scioto, WarrenKentucky: Boone, Campbell, Grant, KentonIndiana: Dearborn, Franklin, Ohio, Ripley, Switzerland

Updated: 8/1/2008


10/62

Ohio Common Grant FormGRANT APPLICATION SHORT FORM

7

SECTION THREE - STATEMENT OF NEED

1) What is the problem, challenge or need that is unaddressed or unmet? Or what is thecommunity benefit that this program or project will impart?

Cancer is the second most frequent cause of death in USA and causes the loss of over 500,000American lives every year. Despite these dreadful figures, major advances in diagnosis andtherapy have increased the life expectancy and even the cure rate of some cancer types. One ofthe major cornerstones of cancer therapy is the use of chemotherapeutic cytostatic drugs thatblock the proliferation of cancer cells. Unfortunately, a major side effect of these therapies is thedevelopment ofa disease called bone marrow (BM) failure (BMF) because of specific toxicityon the proliferating compartment of blood-forming (hematopoietic) stem cells (HSC). Stem cellsare the mother cells required for blood production. They are located in the bone marrow and areresponsible for all the circulating blood cells. Bone marrow failure induced by a failure (ordeficiency) of stem cell function is a major cause of morbidity and mortality in patients

undergoing cancer therapy.

2) What is the research, statistic(s) or evidence that shows this-need or benefit exists?

Redacted

Updated: 8/1/2008


11/62

mOhio Common Grant FormGRANT APPLICATION SHORT FORM

8


12/62

f / S J Ohio Common Grant Form 9

REFERENCES

1. Marsh, J.C., Chang, J., Testa, N.G., Hows, J.M., and Dexter, T.M. 1991. In vitro assessment of

marrow 'stem cell' and stromal cell function in aplastic anaemia. Br JHaematol 78:258-267.

2.Young, N. 1994. Pathophysiology. I. Stem cells, stroma, and growth factors. YoungNS, Alter

BP (eds): Aplastic anemia, acquired andinherited. Philadelphia, WB Saunders,.3.Liu, Y., Elf, S.E., Miyata, Y., Sashida, G., Liu, Y., Huang, G., Di Giandomenico, S Lee, J.M.,

Deblasio, A., Menendez, S., et al. 2009. p53 regulates hematopoietic stem cell quiescence. CellStem Cell 4:37-48.

4.Cheng, T., Rodrigues, N., Shen, H., Yang, Y., Dombkowski, D., Sykes, M., and Scadden, D.T.2000. Hematopoietic stem cell quiescence maintained by p21cipl/wafl. Science 287:1804-

1808.5.Li, J., Zhang, X., Sejas, D.P., and Pang, Q. 2005. Negative regulation of p53 by nucleophosmin

antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. LeukRes 29:1415-1423.

6.Zhang, X., Li, J., Sejas, D.P., and Pang, Q. 2005. The ATM/p53/p21 pathway influences cell

fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitorcells. JBiol Chem 280:19635-19640.7.Zhang, X., Sejas, D.P., Qiu, Y., Williams, D.A., and Pang, Q. 2007. Inflammatory ROS

promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence. JCellSci 120:1572-1583.

8.Berardi, A.C., Wang, A., Levine, J.D., Lopez, P., and Scadden, D.T. 1995. Functional isolationand characterization of human hematopoietic stem cells. Science 267:104-108.

Updated: 8/1/2008


13/62

r

mOhio Com mon Grant Form 10GRANT APPLICATION SHORT FORM

9.Hwang, P.M., Bunz, F., Yu, J., Rago, C, Chan, T.A., Murphy, M.P., Kelso, G.F., Smith, R.A,Kinzler, K.W., and Vogelstein, B. 2001. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis incolorectal cancer cells. NatMed 7:1111-1117.

lO.Rosendaal, M., Green, C.R., Rahman, A., and Morgan, D. 1994. Up-regulation of theconnexin43+ gap junction network in haemopoietic tissue before the growth of stem cells. /

CW/Sci 107 (Ptl):29-37.11.Chambers, S.M., Boles, N.C., Lin, K.Y., Tierney, M.P., Bowman, T.V., Bradfute, S.B., Chen,

A.J., Merchant, A.A., Sirin, O., Weksberg, D.C., et al. 2007. Hematopoietic fingerprints: anexpression database of stem cells and their progeny. Cell Stem Cell 1:578-591.

12.Forsberg, E.C., Prohaska, S.S., Katzman, S., Heffher, G.C., Stuart, J.M., and Weissman, IX.

2005. Differential expression of novel potential regulators in hematopoietic stem cells. PLoSGenet \\QZ%.

13.Spray, D.C. 1998. Gap junction proteins: where they live and how they die. Ore Res 83:679-681.

14.Goodenough, D.A., and Paul, DX. 2003. Beyond the gap: functions of unpaired connexonchannels. Nat Rev Mol Cell Biol 4:285-294.

15.Goubaeva, F., Mikami, M., Giardina, S., Ding, B., Abe, J., and Yang, J. 2007. Cardiacmitochondrial connexin 43 regulates apoptosis. Biochem Biophys Res Commun 352:97-103.

16.Cottin, S., Ghani, K., and Caruso, M. 2008. Bystander effect in glioblastoma cells with apredominant cytoplasmic localization ofconnexin43. Cancer Gene Ther15:823-831.

17.Francis, R.J., and Lo, C.W. 2006. Primordial germ cell deficiency in the connexin 43knockout mouse arises from apoptosis associated with abnormal p53 activation. Development133:3451-3460.

18.Cancelas, J.A., Koevoet, W.L., de Koning, A.E., Mayen, A.E., Rombouts, E.J., andPloemacher, R.E. 2000. Connexin-43 gap junctions are involved in multiconnexin-expressingstromal support of hemopoietic progenitors and stem cells. Blood96:498-505.

19.Presley, C.A., Lee, A.W., Kastl, B., Igbinosa, L, Yamada, Y., Fishman, G.L, Gutstein, D.E.,

and Cancelas, J.A. 2005. Bone marrow connexin-43 expression is critical for hematopoieticregeneration after chemotherapy. Cell Commun Adhes 12:307-317.

20.Hirst-Jensen, B.J., Sahoo, P., Kieken, F., Delmar, M., and Sorgen, PX. 2007. Characterizationof the pH-dependent interaction between the gap junction protein connexin43 carboxylterminus and cytoplasmic loop domains. JBiol Chem 282:5801-5813.

21.Revilla, A., Castro, C, and Barrio, L.C. 1999. Molecular dissection of transjunctional voltagedependence in the connexin-32 and connexin-43 junctions. Biophys .777:1374-1383.

22.Tong, D., Li, T.Y., Naus, K.E., Bai, D., and Kidder, G.M. 2007. In vivo analysis of undockedconnexin43 gap junction hemichannels in ovarian granulosa cells. J Cell Sci 120:4016-4024.

Updated; &/1/2008


14/62

Ohio Common Grant Form 11GRANT APPLICATION SHORT FORM

SECTION FOUR- PROGRAM/PROJECT DESCRIPTION & METHODOLOGY

IMPORTANT: Review the funder'sprogram guidelines and restrictions before responding to thissection.

1) Description of program/project, including:a) Summary description of overall program/project to be funded under this grant

b) Brief description of go als and obj ectives for pro gram/proj ect

Updated: 8/1/2008


15/62

Tj{S& Ohio Co mm on Grant For m 12I ^ S J GRANT APPLICATION SHORT FORM

Specific Aim 1 will be developed during Yr 1 and Yr 2. Specific Aim 2 will be developed

during the second half of Yr 2 and Yr 3.

d) Evidence of use of best practices (For example, is this program/project based on a program

that has been shown to be effective in other settings? Is it based on national standards?). Ifthe initiative is a pilot project and has not been done before, please list assumptions on why

new approach will succeed.

The design of this project is based on the best practices of use of transgenic animal models to

study a specific mechanism in physiology or disease in vivo deprived of all the confounding

factors encountered in human specimens. Our group and others have already demonstrated

efficacy applying this design to specific questions on stem cell biology. Examples of the

publications related to our experience in this field can be found below:

1. Cancelas JA, Koevoet JLM, De Koning AE, et al. Connexin-43 gap junctions are involved in

multiconnexin-expressing stromal support of hemopoietic progenitors and stem cells. Blood2000;96:498-505.

2. Puig T, Kadar E, Limon A, Cancelas JA, et al. Myeloablation enhances engraftment of transducedmurine hematopoietic cells but does not influence long-term expression of the transgene. GeneTherapy 2002;9:1472-9.

3. Gu Y, Filippi MD, Cancelas JA, et al. Hematopoietic cell regulation by Racl and Rac2 guanosinetriphosphatases. Science 2003;302:445-9.

4. Jansen M, Yang FC, Cancelas JA, et al. Rac2-deficient hematopoietic stem cells show defectiveinteraction with the hematopoietic microenvironment and long- term engraftment failure. Stem Cells2005;23:335-346.

5. Cancelas JA, Lee AW, Prabhakar R, et al. Racl and Rac2 Rho GTPases distinctly regulate bonemarrow hematopoietic stem cell localization and are novel targets for stem and progenitor cell

mobilization. NatMed 2005;11(8):886-91.6. Chandra S, Levran O, Jurickova I, et al. A rapid method for retrovirus mediated identification ofcomplementation groups in Fanconi anemia patients. Mol Ther 2005;12(5):976-84.

7. Presley CA, Lee AW, Kastl B, et al. Bone marrow connexin-43 expression is critical forhematopoietic regeneration after chemotherapy. Cell Commun Adhes 2005;12(5-6):307-17.

8. Yamada Y, Rothenberg ME, Lee AW, et al. The FIPJLl-PDGFRa fusion gene cooperates with IL-5to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-likedisease. Blood 2006;107(10):4071-9.

9. Cancelas JA, Jansen M, Williams DA. The role of chemokine activation of Rac GTPases inhematopoietic stem cell marrow homing, retention and peripheral mobilization. Exp Hematol2006,34(8):976-85.

10. Cancelas JA, Williams DA. Stem cell mobilization by B2-agonists. Nat Med 2006,12(3):278-9.

11. Akbar H, Cancelas JA, Williams DA, Zheng J, Zheng Y. Rational design and applications of a RacGTPase-specific small molecule inhibitor. Methods Enzymol 2006;406:554-65.

12. Nassar N, Cancelas J, Zheng J, Williams DA, Zheng Y. Structure-function based design of smallmolecule inhibitors targeting Rho family GTPases. Curr Top Med Chem 2006;6:1109-16.

13. Ghiaur G, Lee A, Bailey J, Cancelas JA, Zheng Y, Williams DA. Inhibition of RhoA GTPase activityenhances hematopoietic stem and progenitor cell proliferation and engraftment in vivo. Blood2006;108(6):2087-94.

14. AuBuchon JP, Cancelas JA, Herschel L, et al. hi vitro and in vivo evaluation of LEUKOSEP HRC-600-C leukocyte reduction filtration system for red cells. Transfusion 2006;46:1311-4.

Updated: 8/1/2008


16/62

^ / S J Ohio Common Grant Form 13^ \ 5 j GRANT APPLICATION SHORT FORM

15. Williams DA, Xu H, Cancelas JA. Children are not little adults: just ask their hematopoietic stemcells. J Clin Invest 2006; 116:2593-6.

16. Williams DA, Cancelas JA. Leukaemia: niche retreats for stem cells. Nature 2006;444:827-8.

17. Yamada Y, Rothenberg ME, Cancelas JA. Current concepts on the pathogenesis of thehypereosinophilic syndrome/chronic eosinophilic leukemia. Translational OncoGenomics 2006;2:53-

63.18. Kelly PF, Radtke S, von Kalle C, et al. Collection and genetic correction of Fanconi anemia

hematopoietic stem cells. Mol Ther 2007;15(1):211-9.

19. Bandarenko N, Cancelas JA, Snyder E, et al. Successful in-vivo recovery and extended storage ofadditive solution (AS)-5 red blood cells after deglycerolization and resuspension in AS-3 for 15 dayswith an automated closed system. Transfusion 2007;47:680-6.

20. Yang L, Wang L, Geiger H, Cancelas JA, Mo J, Zheng Y. Rho GTPase, CDC42, coordinateshematopoietic stem cell quiescence and niche interaction in the bone marrow. PNAS 2007;104:5091-6.

21. Akbar H, Kim J, Funk K, Cancelas JA, et al. Genetic and pharmacological evidence that RaclGTPase is involved in regulation of platelet secretion and aggregation. J Thrombosis Hemost2007;5(8):1747-55.

22. Thomas EK*, Cancelas JA*, Chae HD, et al. Rac guanosine triphosphatases are critical for thedevelopment of BCR/ABL-mediated chronic myeloid leukemia-like myeloproliferative disease.Cancer Cell 2007;12(5):467-78. (*co-first author).

23. Yang L, Wang L, Kalfa T, Cancelas JA, Mo J, Williams DA, Zheng Y. Cdc42 critically regulates thebalance between myelopoiesis and erythropoiesis. Blood 2007;110(12):3853-61.

24. Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neurofibromas and pigmentation are causedby Nfl loss in desert hedgehog expressing cells. Cancer Cell 2008;13(2): 105-16.

25. Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM,Cripe TP. Oncolytic HSV-1 expressing tissue inhibitor of metalloproteinases-3 enhances antitumorefficacy and reduces circulating endothelial progenitors. Cancer Res 2008;68(4): 1170-9.

26. Ghiaur G, Ferkowicz MJ, Milsom MD, Bailey J, Cancelas JA, Yoder MC, Williams DA. Racl isessential for intra-embryonic hematopoiesis and for the initial seeding of fetal liver with definitivehematopoietic progenitor cells. Blood 2008 Apr 1;111(7):3313-21 Epub 2007 Dec 21.

27. Williams DA, Zheng Y, Cancelas JA. Rho GTPases and regulation of hematopoietic stem cell

localization. Methods in Enzymology 2008;439:365-93.

28. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JE, Zheng Y, Cancelas JA, Gu Y,Jansen M, DiMartino JF, Mulloy JC. Microenvironment determines lineage fate in a human model ofMLL-AF9 leukemia. Cancer Cell 2008;13(6):483-95.

29. Thomas EK, Cancelas JA (co-first author), Zheng Yi, Williams DA. Rac GTPases as key regulatorsof p210-BCR-ABL-dependent leukemogenesis. Leukemia 2008;439:365-93.

30. Yamada Y, Sanchez-Aguilera A, Brandt EB, McBride M, Al-Moamen NJ, Finkelman FD, WilliamsDA, Cancelas JA*, Rothenberg ME* (*both authors contributed equally). FIPlLl/PDGFRasynergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilicleukemia/hypereosinophilic syndrome. Blood 2008, 112(6):2500-7.

31. Guo F, Cancelas JA, Hildeman D, Williams DA, Zheng Y. Rac GTPase isoforms, Racl and Rac2,

play a redundant and crucial role in T-cell development. Blood. 2008, 112(5): 1767-75.

32. Muller LUW, Schore RJ, Zheng Y, EIC Thomas, Kim M-O, Cancelas JA, Williams DA. Racguanosine trisphosphatases represent a potential target in AML. [Letter] Leukemia 2008Sep;22(9): 1803-6.

Updated: 8/1/2008


17/62

fjfSJ Ohio Common Grant Form 14l \ 5 j GRANT APPLICATION SHORT FORM

33. Williams JP, Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H, MalikP, Li W, Mukouyama Y,Cancelas JA, Ratner N. Nfl mutation expands an EGFR-dependent peripheral nerve progenitor thatconfers neurofibroma tumorigenic potential. Cell Stem Cell 2008 Dec 4;3(6):658-669.

34. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, CripeTP. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a

targeted oncolytic virus. PLoS ONE 2009;4(1): e4235 doi:10.1371/journal.pone.0004235.35. Cancelas JA, Williams DA. Rho GTPases in hematopoietic stem cell functions. Curr Opin Hematol

2009Jul;16(4):249-54.

36. Yamada Y, Cancelas JA, Rothenberg ME. Murine model of hypereosinophilic syndromes/chroniceosinophilic leukemia, hit Arch Allergy Immunol 2009; 149(Suppl 1): 102-7.

37. Milsom MD, Lee AW, Zheng Y, Cancelas JA. Fanca"'" hematopoietic stem cells demonstrate amobilization defect which can be overcome by administration of the Rac inhibitor NSC23766.Haematologica 2009;94:1011-5.

Updated; 8/1/2008


18/62

r

mOhio Common Grant Form 15GRANT APPLICATION SHORT FORM

2) Brief description of how grant funds will be used?

1) Personnel:a. Principal Investigator (Jose Cancelas) 0% effort supported by this grant.b. Postdoctoral Fellow (KyungHee Chang) 100% effort. $167,649.

c. Research Assistant (Elisabeth Hartman) 50% effort. $69,334.

2) Animals and Reagents:a. Purchase of animals, husbandry and reagents; $107,907.

Hoxworth Blood Center will aclcnowledge the funder in publications that result from this project.We will also recognize the funder in our annual report, web page, and press release in conjunctionwith the funder's wishes.

Updated: 8/1/2008


19/62

fjfSj] Ohio Common Grant Form 16^ \ 5 | GRANT APPLICATION SHORT FORM

SECTION FIVE - EVALUATION AND RESULTS

1) Complete the Program/Project Evaluation Chart at the end of this document.

SECTION SIX - PROGRAM/PROJECT FUNDING PLANS

1) List of other funders to whom this current proposal has been and will be submitted. Foreach funder, indicate amount requested and status of request (e.g. "to be submitted,""pending," "funded," or "declined"). If funded, specify amount of grant and date received.

1. This project is partly funded by the National Blood Foundation ($37,500/year for2 years).

2. To be submitted: Department of Defense (Bone Marrow Failure call-for-proposals) and National Institutes of Health. Our goal is to obtain overall funding forthis project reaching $1,500,000, including $1,080,110 from the Federal Government.

2) Other anticipated funding for this current proposal including:a) Earned revenue$0b) In-kind support$0c) Special events$0d) Fundraisers, etc.$0

3) If this will be an ongoing program/project, describe plans and specific sources forfuture/long-term funding.

This project is expected to provide results in a 5-year period. A long-term goal is thedevelopment of therapeutic tools that can be used in cancer therapy to minimize or amelioratebone marrow failure secondary to chemotherapy treatment. We anticipate that funding will beneeded for this latter phase. We are part of the NIH-funded PACT for Cell Therapy projects andwe envision that future clinical trials may be funded by National Institutes of Health, Food andDrug Administration or Dept. of Defense

Updated: 8/1/3008


20/62

r ^ & j Ohio Common Grant Form 17^ S \ GRANT APPLICATION SHORT FORM

SECTION SEVEN - REQUIRED FINANCIAL ATTACHMENTS

1) Statement of Revenue/Support and Expense* for your organization's most recentlycompleted fiscal/calendar year.

2) Total Organizational Budget for Current Fiscal Year* including a column showing theorganization's year-to-date status.

3) Project Request Budget* for your entire project.

^Available as a common form

SECTION EIGHT - REQUIRED NON-FINANCIAL ATTACHMENTS

1) IRS letter of determination 501(c)(3), or if such a letter does not exist see specific funderrequirements

2) Names and professional affiliations of board members

Before using the Common Grant Application, please visit thefunder's website or call to learn additional

information about the funder and how it uses the Application

The Common Grant Application is a collaborative effort offunder and nonprofit organizations working to build theperformance capability of the nonprofit sector in Ohio.

Updated: 8/1/2008


21/62

r ^ S J Ohio Common Grant Form 18^ 5 ] GRANT APPLICATION SHORT FORM

GLOSSARY

Capital Request - A planned undertaking to purchase, build or renovate a space or building, or

to acquire equipment.

In-Kind Support - A contribution of equipment/materials, time, and or services that the donorhas placed a monetary value on for tax purposes.

Methodology - A sequence of activities needed to accomplish the program objectives.

Operational Support - A grant given to cover an organization's day-to-day expenses such assalaries, utilities, office supplies, etc.

Outcomes - The changes in (or benefits achieved by) individuals or communities due to theirparticipation in program/project activities. This may include changes to participants' knowledge,skills, values, behavior, or condition of status. In general, outcomes are described in quantitativeor qualitative terms.

Quantitative (or Measurable) outcomes are changes or benefits that can be measured orcounted and expressed with a numerical value. For example, 30 of the 40 third-gradestudents participating in the literacy program will increase their reading level by onegrade level.

Qualitative outcomes are changes or benefits that refer only to the characteristics ofsomething being described, rather than exact numerical measurement. Qualitative

changes can be observed (or detected through the senses) and are generally described in anarrative form. For example, the mother ofa student participating in the literacy programstated that her daughter no longer feared reading aloud in class now that she could read atthe same level as her classmates.

Program - An organized set of services designed to achieve specific outcomes for a specifiedpopulation that will continue beyond the grant period.

Project - A planned undertaking or organized set of services designed to achieve specificoutcomes that begins and ends within a specified time period. (A successful project may becomean ongoing program.)

Technical Assistance - Operational or managerial assistance given to a nonprofit organization.It may include fundraising assistance, budgeting or financial planning, program planning, legaladvice, marketing or other aids to management. Assistance may be offered directly by afoundation or corporate staff member or in the form ofa grant to pay for the services ofaconsultant.

Updated: 8/1/2008


22/62


19

PROGRAM/PROJECT EVALUATION CHART

Program/Project Ontcomefs)The ultimate result ofa program/

project

Program/Project MeasuresMeasurable results of a program/

project

Benchmark ($, #, %,yes/no)

*Note: NO TEXT other thanyes/no should be included in thisfield

Example 1:To help children read better. Children will improve their

reading scores by one grade level, 50

Example 2:Diversity the agency's revenuesources and increase its financialstability

Hire a part-time developmentdirector.Increase private donations during2006.Increase earned revenue during2006.

Yes

30%

25%

Elucidation of the role of

R e d a c t e dn t h e

aevelopment of bone marrow

failure after cancer therapy.

Pre-clinical proof-of-concept to

support the R e d a c t e d

R edac ted to prevent

chemotherapy-induced toxicity.

Fund a research postdoctoral

fellow and 50% effort of one

research assistant.

Fund part of the reagents and

animal expenses

Obtain preliminary data

sufficient to obtain federal

funding (e.g., NIH, Dept. of

Defense)

Yes, 1.5FTE

Yes.

Yes, $1,080,110

Updated; 0/1/2008


23/62

f i fSJ Ohio Common Grant Form 1^ S \ GRANT APPLICATION SHORT FORM

Dear Nonprofit Colleague,

The Grant ApplicationShort Form was developed by a task force ofOhio Grantmakers Forum(OGF) as part of a series of statewide common grant forms. OGF and its members created thisform to make the grantseeking process simpler and more efficient for nonprofits.

Please keep in mind that every funder has different guidelines and priorities, as well as differentdeadlines and timetables. Before submitting this application to a potential grantmaker, it isvery important that you check to see whether your project or program matches theirpublished interests. Any funder that has agreed to accept this form may request additionalinformation as needed. In addition, a funder may require that a grantseeker complete the longerGrantApplication. Please check with the funder which form they require.

STRATEGIES FOR SUCCESSFUL GRANTSEEKING

1. Do your research to determine whether the foundations' and corporations' goals andobjectives for grantmaking are consistent with your type of grant request.2. After you do the research, find out the preferred method of contact for the grantmaker, and

contact the grantmaker to secure their specific grantmaking guidelines. Many fundersgenerally like to have initial contact with you before receiving a written proposal.

3. Complete the letter of inquiry for those funders that require that form BEFORE completingthis common application. The funder's guidelines will state whether a letter of inquiry isrequired or not.

4. Include a cover letter with each proposal that introduces your organization and yourproposal, and makes a strategic link between your proposal and the funder's mission andgrantmaking interests.

5. Provide responses that are typed, single-spaced, single-sided and use a 12-point type.6. Answer all the questions in each section, UNLESS otherwise indicated by the funder. Atthe funder's discretion, you may answer the questions individually or group then into onenarrative for each section (for Sections Two to Six).

7. Submit the number of copies each grantmaker requests according to their guidelines.8. Do not include any materials other than those specifically requested at this time.9. If completing an online application, you are strongly encouraged to fill out and save the

Microsoft Word version of the common grant applicationshort form on your computer.Then proceed to cut and paste the requested information into the funder's online application.

RESOURCES

Call, write or check the website of each grantmaker to obtain a copy of their fundingguidelines.

Use OGF's Guide to Ohio Grantmakers and other directories listing foundations' interestsand processes.

Visit a Foundation Center Cooperative Collection which can be located atwww.fdncenter.org/cleveland.

Updated; 8/1/2008
http://www.fdncenter.org/clevelandhttp://www.fdncenter.org/clevelandhttp://www.fdncenter.org/cleveland


24/62

r^fSd Ohio Common Grant Form 2J L S j GRANT APPLICATION SHORT FORM

To download this form, visit OGF's website at:www.ohiograntmakers.org

SECTION ONE

Funder to which this application isdirected

The Heimlich Institute

Date of Application 10/16/09

ORGANIZATION INFORMATION

Applicant Organization (Full Legal Name) The University of Cincinnati Foundation

Doing Business As

Previous Name, if changed

IRS letter date 1-24-1977

Tax Exempt ID # (EIN) 31-0896555

Name of Executive DirectorMichael Carroll - University of CincinnatiFoundationRonald A. Sacher, MD - Hoxworth

Name of Fiscal Sponsor (if applicable)

CONTACT INFORMATION

Proposal Contact Name Scott Inscho

Title Division Director, FinancePhone 513-558-1243

Fax 513-558-1253

E-mail [email protected]

Street Address Hoxworth Blood Center, 3130 Highland Avenue

City Cincinnati

State Ohio

Zip Code 45267-0055Organization Website Hoxworth.org

Mail ing A ddre ss (if different than streetaddress)

City

State

Updated: 8/1/2008
http://www.ohiograntmakers.org/mailto:[email protected]://hoxworth.org/http://hoxworth.org/mailto:[email protected]://www.ohiograntmakers.org/


25/62

Tfmk Ohio Common Grant Form 3^ S \ GRANT APPLICATION SHORT FORM

Zip Code


26/62

r^Sjj Ohio Common Grant Form 4k l f f i GRANT APPLICATION SHORT FORM

ORGANIZATION FINANCIAL INFORMATION

Organization's Budgeted Expenses forCurrent Year (givefiscalyear end mm/dd/yy)

$40,135,674 06/30/10

Endowment Size (market value asof fiscalyear mm/dd/yy)

$0

Organization's Major Funding Sourcesby percentage (e.g., United Way, localcommunity foundation, county board of health,etc.)

Revenues from sales of blood products andservices.

ORGANIZATION'S AFFILIATION

United Way Kl Other specify: University of Cincinnati [3 Chapter of national orregional organization

specify: AABB, America's Blood Centers, Blood Centers of America

REQUEST DATA

Program/Project TitleCellular Immunotherapy for viral diseases,post transplant.

Total Budget for this Program/Project $313,110

Amount of this request $313,110

Grant Duration (e.g., one-year, two-year,etc.)

3 years

Anticipated Project Start Date December 1, 2009

Community/Counties served by thisProgram/Project

National - as patients are referred toCincinnati Children's Hospital.

Total Number of people to be served during

grant period

NA-Developmental

Brief demographic description of populationserved by this Program/Project

Bone Marrow Transplant Patients atCincinnati Children's Hospital Medical Center

TYPE OF REQUEST (check all that apply)

Capital X Technical assistance Operating Endowment

X Program/Project Start-up DOther - specify:

SIGNATURES {both are required unless otherwise specified by funder)

Signature of Executive Director

Signature of Board President

"TV

Updated; 8/1/2008


27/62

f / S d Ohio Common Grant Form 5J k 5 | GRANT APPLICATION SHORT FORM

In general, the following narratives, which include Sections Two through Six, should not exceedfive pages in total {please confirm any page limits with each foundation to which you aresubmitting the application). Responses should be typed, single-spaced, single-sided and use a12~point type. At the fiinder's discretion, you may answer questions individually or group theminto one narrative for these sections {Section Two to Section Six).

SECTION TWO - ORGANIZATIONAL BACKGROUND

1) Brief summary of organization's history and statement of organization's mission

Hoxworth Blood Center is one of the oldest community blood centers in the country.Founded in December, 1938 by Cincinnati surgeon Paul I. Hoxworth, MD, the blood bankwas first established as a not-for-profit organization operating under the auspices of the

Cincinnati and Hamilton County Chapter of the American Red Cross. As World War IIbegan to draw to a close, the American Red Cross turned the blood bank over to theUniversity of Cincinnati (UC) College of Medicine and it became known as the UC Blood

. Transfusion Service. The blood center was renamed for its founder in 1973.

Today, more than 250 employees staff Hoxworth's main facility, nine neighborhood donorcenters, and its mobile collection operations. The blood center distributes more than 200,000blood components annually. Hoxworth serves 32 hospitals and medical centers in a 17-county region in Ohio, Kentucky and Indiana, and relies on 350 donors daily to meet theneeds of tri-state patients. Hoxworth is the tri-state's only blood center.

Our mission is to enhance the well being of patients in our service area by assuring areliable and economical supply of the safest possible blood, by providing innovativehemotherapy services, and by promoting research and education programs in transfusionmedicine.

2) Brief description of current programs/projects and activities

Hoxworth Blood Center, University of Cincinnati Academic Health Center, is the onlyblood center for the greater Cincinnati area. Hoxworth is a component of the University ofCincinnati and is therefore governed by the University of Cincinnati Board of Trustees.Hoxworth does have a Community Advisory Board and a Medical and Technical AdvisoryCommittee. In addition to providing blood products to the tri-state's 32 hospitals, Hoxworth

also processes progenitor cells for transplants, provides tissue-typing services and has astrong transfusion medicine research program. Hoxworth also has graduate and postgraduate programs in transfusion medicine. Hoxworth is licensed and regulated by the U.S.Food and Drug Administration and accredited by the AABB (formerly known as theAmerican Association of Blood Banks), the American Society for Histocompatibility andImmunogenetics, and the Foundation for the Accreditation of Cell Therapies. Hoxworth isalso a member of America's Blood Centers and Blood Centers of America.

Updated; a/1/2008


28/62

r^SJ Ohio Common Grant Form 6^ 5 ] GRANT APPLICATION SHORT FORM

3) Evidence of organization's overall effectiveness based on achievement of specific

organizational of program goals

Major achievements in the past two years include:-Hoxworth collected over 178,000 red blood cell units.

-Hoxworth received a $15,000 gift from the Bernard and Pamela Barbash Foundationtoward a new Hoxworth bloodmobile.-Hoxworth started to collect blood from 16 year-old donors on August 27, 2008. We havecollected 2,436 units from these donors.-Dr. Jose Cancelas, Division Director of Research, was awarded the 2008 David B. Pallprize for innovative research in transfusion medicine. This award recognizes a scientistwhose original research resulted in an important contribution to the body of scientificknowledge. The recipient is selected by the National Blood Foundation Scientific GrantsReview Committee.-Hoxworth began providing a new service, photopheresis therapy, where instrumentationand medication are used to treat chronic graft vs. host disease, cutaneous T cell lymphoma

and heart-transplant rejection.-Hoxworth implemented a new branding initiative that resulted in a new logo and brandingfor Hoxworth.-Hoxworth welcomed the West Chester Medical Center to our family of customers. Thisnew hospital opened in early May 2009.-Hoxworth's Cell Therapy Division has been working with the UC Department of Surgeryto provide processing and quality assurance support for their autologous pancreatic islet cellisolation procedure.

4) Description of population and geographic region (community/county) served by this

organization

Counties served by Hoxworth Blood Center:Ohio: Adams, Butler, Brown, Clermont, Hamilton, Highland, Scioto, WarrenKentucky: Boone, Campbell, Grant, KentonIndiana: Dearborn, Franklin, Ohio, Ripley, Switzerland

Updated; 8/1/2008


29/62


SECTION THREE - STATEMENT OF NEED

1) What is the problem, challenge or need that is unaddressed or unmet? Or what is thecommunity benefit that this program or project will impart?

Immunocompromized patients such as the bone marrow transplant patients atCincinnati Children's Hospital have defective immune systems and are thus athigh risk for acquiring life-threatening viral infections during their recoveryperiod, especially those caused by cytomegalovirus (CMV), Epstein-Barr virus(EBV) and adenovirus. Conventional anti-viral therapeutic agents are primarilyactive only against CMV, and resistance is frequent, therefore these infections areoften fatal for these children.

2) What is the research, statistic(s) or evidence that shows this need or benefit exists?

Severe viral disease is a major cause of morbidity and mortality inimmunocompromised individuals such as bone marrow transplant survivors.Approximately 60% of the approximately 75 patients that receive allogeneic bonemarrow transplants at CCHMC each year acquire a viral infection within the firstyear post-transplant, while their immune system is still recovering.Approximately 10% of those viral infections prove fatal with conventionaltherapy, thus approximately 5 patients from the transplant program alone die eachyear from a viral infection that does not respond to conventional anti-viraltherapy. If the same statistics hold up for other types of immunocompromisedpatients, then this experimental therapy would potentially benefit many

individuals.

Updated: 8/1/20G8

:


30/62


Redacted

REFERENCE:

8

Leen, AM, Myers GD, Sili U, et.al. Monoculture-derived T lymphocytes specificfor multiple viruses expand and produce clinically relevant effects inimmunocompromised individuals. 2006. Nature Medicine 12(10):1160-1166.

SECTION FOUR - PROGRAM/PROJECT DESCRIPTION & METHODOLOGY

IMPORTANT: Review the funder'sprogram guidelines and restrictions before responding tothis section.

1) Description of program/proj ect, including:a) Summary description of overall program/project to be funded under this grant

Updated: 8/1/20Q8


31/62

[01Ohio Common Grant FormGRANT APPLICATION SHORT FORM

b) Brief description of goals and objectives for program/proj ect

c) Timetable for implementation and duration of program/project

It is anticipated that this project could be initiated in Ql 2010 and that it will take2.5 to 3 years to achieve FDA approval for this clinical trial.

d) Evidence of use of best practices (For example, is this program/project based on aprogram that has been shown to be effective in other settings? Is it based on nationalstandards?). If the initiative is a pilot project and has not been done before, please listassumptions on why new approach will succeed.

Updated: 8/1/2008


32/62

mOhio Common GrantFormGRANT APPLICATION SHORT FORM

10

REFERENCE: Fujita Y, Rooney CM, and Heslop HE. Adoptive cellularimmunotherapy for viral diseases. 2008. Bone Marrow transplantation 41:193-198.

2) Brief description of how grant funds will be used?

The grant funds will be used to:

Hire technical staff into Hoxworth's Cellular Therapy division to perform the

experiments required to develop ^ ^ ^ ^ ^ ^ R e d a c t e d B W M ^ B

^^^^^^^^^^ ^^ sEfffsTSRsfE^H^H^^^H^^^IHromLeemhuis, Lab Director for Roxwortct, would be funded at 10% for the firsttwo years and 5% for the last year. A Research Assistant would be funded at60% for the first two years and 30% for the last year.

Compensate Hoxworth for the Laboratory Director's time and effort organizingexperiments, reviewing da ta .^^^ ^^^^ Hf ls fS ls TS ns fS ^^^^ ^^^H , and

Purchasing IRedacted

RedactedRedacted

Redacted Purchasing the|

Sending a Technologist to Baylor University to receive training onl

RedactedRedacted

RedactedCommunicating results at a national / international meeting.

Hoxworth Blood Center will provide the cleanroom facility and the majority of theequipment required for this project. Hoxworth Blood Center will acknowledge thefunder in publications that result from this project. We will also recognize the funder inour annual report, web page, and press release in conjunction with the funder's wishes.

SECTION FIVE - EVALUATION AND RESULTS

1) Complete the Program/Project Evaluation Chart at the end of this document.

SECTION SIX- PROGRAM/PROJECT FUNDING PLANS

Updated: B/1/2008


33/62


11

1) List of other funders to whom this current proposal has been and will be submitted. Foreach funder, indicate amount requested and status of request (e.g. "to be submitted,""pending," "funded," or "declined"). If funded, specify amount of grant and date received,

This proposal has not been submitted to any other potential funding source. It is

rare for us to be able to obtain funding for process development objectives, thuswe do not plan to submit this proposal to any other funding agency in the nearfuture.

2) Other anticipated funding for this current proposal including:a) Earned revenue

None

b) In-kind support

Baylor University will be providing expert technical support throughout the project at no

cost to Hoxworth.

c) Special eventsNone

d) Fundraisers, etc.None

3) If this will be an ongoing program/project, describe plans and specific sources for

future/long-term funding.

CCHMC has historically been able to provide funds for phase 1 clinicaltrials with the potential for significant outcome improvement once proofof principle experiments are complete. Redacted

SECTION SEVEN - REQUIRED FINANCIAL ATTACHMENTS

1) Statement of Revenue/Support and Expense* for your organization's most recentlycompleted fiscal/calendar year.

2) Total Organizational Budget for Current Fiscal Year* including a column showing theorganization's vear-to-date status.

3) Project Request Budget* for your entire project.

* Available as a common form

Updated: 8/1/2008


34/62

f / 2 J Ohio Common Grant Form 12^ 5 ] GRANT APPLICATION SHORT FORM

SECTION EIGHT - REQUIRED NON-FINANCIAL ATTACHMENTS

1) IRS letter of determination 501(c)(3), or if such a letter does not exist see specific funderrequirements

2) Names and professional affiliations of board members

Before using the Common Grant Application, please visit thefunder's website or call to learn additional

information about the funder and how it uses the Application

The Common Grant Application is a collaborative effort offunder and nonprofit organizations working to build theperformance capability of the nonprofit sector in Ohio.

Updated: 8/1/2008


35/62

FjfSJ Ohio Common Grant Form 13^ S \ GRANT APPLICATION SHORT FORM

GLOSSARY

Capital Request - A planned undertaking to purchase, build or renovate a space or building, or

to acquire equipment.

In-ICind Support - A contribution of equipment/materials, time, and or services that the donorhas placed a monetary value on for tax purposes.

Methodology - A sequence of activities needed to accomplish the program objectives.

Operational Support - A grant given to cover an organization's day-to-day expenses such assalaries, utilities, office supplies, etc.

Outcomes - The changes in (or benefits achieved by) individuals or communities due to theirparticipation in program/project activities. This may include changes to participants'knowledge, skills, values, behavior, or condition of status, hi general, outcomes are describedin quantitative or qualitative terms.

Quantitative (or Measurable) outcomes are changes or benefits that can be measuredor counted and expressed with a numerical value. For example, 30 of the 40 third-gradestudents participating in the literacy program will increase their reading level by onegrade level.

Qualitative outcomes are changes or benefits that refer only to the characteristics ofsomething being described, rather than exact numerical measurement. Qualitative

changes can be observed (or detected through the senses) and are generally described ina narrative form. For example, the mother ofa student participating in the literacyprogram stated that her daughter no longer feared reading aloud in class now that shecould read at the same level as her classmates.

Program - An organized set of services designed to achieve specific outcomes for a specifiedpopulation that will continue beyond the grant period.

Project - A planned undertaking or organized set of services designed to achieve specificoutcomes that begins and ends within a specified time period. (A successful project maybecome an ongoing program.)

Technical Assistance - Operational or managerial assistance given to a nonprofit organization.It may include fundraising assistance, budgeting or financial planning, program planning, legaladvice, marketing or other aids to management. Assistance may be offered directly by afoundation or corporate staff member or in the form of a grant to pay for the services of aconsultant.

Updated: 8/1/2008


36/62

:


14

PROGRAM/PROJECT EVALUATION CHART

Proeram/Proiect Outcome(s)The ultimate result ofa program/

project

Proeram/Proiect MeasuresMeasurable results of a program/

project

Benchmark f$, #, %,ves/no)

*Note: NO TEXT other thanyes/no should be included in thisfield

Example 1:To help children read better. Children will improve their

reading scores by one grade level,50

Example 2:Diversify the agency's revenuesources and increase its financialstability

Hire a part-time developmentdirector.Increase private donations during2006,Increase earned revenue during2006.

Yes

30%

25%

FDA approval of the

manufacturing process.

Product meets specified purity,

potency, and safety acceptance

criteria.

All production documents

created and approved for use

Staff training complete

Yes

Yes

Yes

Updated:


37/62

:

Ohio Common Grant FormPROGRAM REQUEST BUDGET

Name of Organization:

Time Period (mm/dd/yy to mm/dd/yy):

(items typical for running a program)

Redacted n bone marrow

REVENUE/SUPPORT Budget

Corporate grants

Foundation grants $344,890


Contributions



Membership dues


Sponsorships

Admissions

Sales, rent

Revenue, tuition

Endowment funds

Interest, dividends, non-endowments investments


Total Revenue/Support $344,890


38/62

: < *


PROGRAM REQUEST BUDGET

Name of Organization:

Time Period (min/dd/yy to mm/dd/yy):

Redacted lin bone marrow

EXPENSES Budget

Salaries $173,868

Employee benefits, taxes $63,114

Affiliate orgs. or contracts (describe in narrative)

Professional fees

Equipment, supplies, materials $107,907

Telephone, utilities

Postage, mailing

Occupancy

Insurance

Training, staff development

Travel

Conferences

Evaluations

Other (describe in narrative if more than 20% oftotalexpenses)

TOTAL EXPENSES $344,890

Revenue less Expenses $0

if expenses exceed revenues/support by more than 10%, please explain how differencewill be offset. Please attach narrative if you have expenses, revenues or a deficit that

require more information or if you believe additional explanation is warranted for any

item.


39/62

FJGA Ohio Common Grant FormA X TOTAL ORGANIZATIONAL BUDGET FOR CURRENT FISCAL YEAR

Name of Organization: i - .'.- th c -.-u;ertpr

Time Period (mm/dd/yy to mm/dd/yy): 9-O6/30/10

REVENUE/SUPPORT Budget for Year

Year-to-Date

8/31/2009

Corporate qrants

Foundation grants


Contributions $30,000$12,095

Affiliate orgs./non-qovt. contracts (describe in narrative)


Membership dues


Sponsorships

Admissions

Sales, rent

Revenue, tuition $41,635,610$7,409,920

Endowment funds

Interest, dividends, non-endowments investments $225,000$48,825

Other (if more than 20% of total revenues, describe in narrative)

Total Revenue/Support $41,890,610$7,510,896


40/62


TOTAL ORGANIZATIONAL BUDGET FOR CURRENT FISCAL YEAR

Name of Organization: Hoxworth Blood Center

Time Period (mm/dd/yy to mm/dd/yy): 07/01/09-06/30/10

EXPENSES Budget for Year

Year-to-Date

8/31/2009

Salaries $13,184,053 $1,882,904

Employee benefits, taxes $5,011,779 $736,528

Affiliate orgs. or contracts (describe in narrative) $0 $0

Professional fees $0 $0

Equipment, supplies, materials $19,846,956 $3,361,769

Telephone, utilities $893,182 $172,123

Postage, mailing $88,500 $18,892

Occupancy $596,340 $111,625

Insurance $211,697 $26,779

Training, staff development $43,280 $3,769

Travel $234,687 $19,032

Conferences $25,200 $77

Evaluations $0 $0

Other (if more than 20% oftotal

expenses, describe in narrative)$0 $0

TOTAL EXPENSES $40,135,674 $6,333,498

Revenue less Expenses $1,754,936 $1,177,398

Please attach written narrative, or include below, for any items above requiring additional explanation. Also explainhow difference will be offset if total expenses exceed total revenues/support by 10% or more.


41/62


STATEMENT OF REVENUE/SUPPORT & EXPENSE (for most recently completed fiscal year)

Name of Organizat ion: Hoxworth Blood Center

Fiscal Year (mm/dd/yy to mm/dd/yy): 07/01/08-6/30/09

REVENUE/SUPPORT

Corporate grants

Foundation grants


Contributions $91,607



Membership dues


Sponsorships

Admissions

Sales, rent

Revenue, tuition $41,276,472

Endowment funds

Interest, dividends, non-endowments investments -$702,377


Total Revenue/Support $40,665,702

m


42/62

PjjiJEjj Ohio Common Grant FormL U R STATEMENT OF REVENUE/SUPPORT & EXPENSE (for most recently completed fiscal year)

Name of Organization: Hcx-.vo*th 3!ooo CeiUr

Fiscal Year (mm/dd/yy to mm/dd/yy): 07/01;'Q3-5:30/C0

EXPENSES

Salaries $12,667,609

Employee benefits, taxes $4,723,718

Affiliate orgs. or contracts (describe in narrative) $0

Professional fees $0

Equipment, supplies, materials $20,684,453

Telephone, utilities $954,937

Postage, mailing $86,073

Occupancy $576,441

Insurance $220,426

Training, staff development $8,164

Travel $195,403

Conferences $21,974

Evaluations $0

Other (describe in narrative if more than 20% of total expenses) $0

TOTAL EXPENSES $40,139,198

REVENUE LESS EXPENSES $526,504

If expenses exceed revenues/support by more than 10%, please explain how difference will be

offset.


43/62

*u . *-W


44/62

If your gross receipts each year are normally more than 85,000,

you are required to file Form 990, Return of Organization Exempt

From Income Tax, by the 15th day of the fifth month after the end

of your annual accounting period. The law imposes a penalty of $10

a day, up to a maximum of S5,'0OO, for failure to file a return on time.

You are not required to file Federal income tax returns unless

you are subject to th-a tax on unrelated business income under section

611 of the Code. If you are subject to this tax, you must file an income

vtax"return on Form 930-T, In this letter we are not determining'whetherany of your present or proposed activities are unrelated trade or

business as defined 'in section 513 of tb.9 Code,

You need an employer identification number eveo if you have no

.employees- If an employer identification number was not.entered on

your application, a number will,be assigned to you and you will be

advised of it. Please use that number on all returns you file and in

all correspondence,with the Internal Revenue Service.

Please keep this determination letter in your permanent records.

Sincerely .yours,

3r7 L. James, 'Jr. Spistrict Director

Inquiries may be directed to:

Joseph Russo

Form L-178 (Rev, 8-73)


45/62

The UC FoundationBoard of Trustees

Active Members

Eugene R. AllspachPresident & COO (Retired)Equistar ChemicalsHouston, TX

Dr. Clark E. Beck, P.E.CEBEC AssociatesDayton, OH

Elroy E. BourgrafChairman, CEOFerno-Washington, Inc.Cincinnati, OH

Henry T. BrownPlant Manager (Retired)Polaroid CorporationWeston, MA

OttoM. Budig, Jr.PresidentBudco Group, Inc.Cincinnati, OH

James E. BushmanDirector, President & CEOCAST-FAB Technologies, Inc.Cincinnati, OH

Daniel P. CarmichaelBaker & DanielsIndianapolis, IN

Todd C. DeGarmo

Principal & CEOSTUDIOS ArchitectureWashington, DC

Thomas E. DeweyConsultantTED ConsultingCincinnati, OH

David B. DillonCEO, Director & ChairmanThe Kroger CompanyCincinnati, OH

Robert E. DobbsVice President, Internal AuditAmerican Financial GroupCincinnati, OH

John S. DomaschkoPresidentMC Squared, Inc.Covington, KY

Dianne G. DunkelmanChief Executive OfficerBuilding Healthy Lives Foundation

Cincinnati, OH

Daniel L. EarleyPresident (Retired)First Clermont BankMilford, OH

Robert L. FealyPresident & Chief Operating OfficerDuchossois Industries, Inc.Elmhurst, IL

William Forbriger, Jr.Executive Vice President (Retired)Tressa, Inc.Ft. Thomas, KY

37


46/62

John B. GoeringGoering Industries (Retired)Crescent Springs, KY

Brian E. HallChairman & CEOIndustrial Transport, Inc.Cleveland, OH

Donald C. Harrison, M.D.Provost EmeritusUniversity of CincinnatiCincinnati, OH

Robert A. HeimannPresidentGlobe CorporationCincinnati, OH

Thomas H. Humes, Jr.PresidentGreat Traditions Land &Development Co.Cincinnati, OH

Timothy E. Johnson, PhDPresidentJohnson Investment Counsel, Inc.

Cincinnati, OH

Barbara A. KellarCommunity VolunteerCincinnati, OH

Patricia L. KlingbielPresident & PrincipalConnell & Associates LLCGlen Rock, NJ

Marvin P. KolodzikPresident, Drives & Components(Retired)Emerson ElectricCincinnati, OH

William H.Krul IIChief Exec Officer & Sr. PartnerMiller-Valentine Partners, Ltd.Dayton, OH

Louis H. Lauch, Jr.PresidentLauch RealtyBatavia, OH

Jerry P. LeamonGlobal Managing PartnerClients & MarketsDeloitte & Touche TohmatsuNew York, NY

Doloris F. Learmonth, Esq.Managing PartnerPeck, Shaffer & Williams LLPCincinnati, OH

William E. LowerCEO/Chairman & PresidentRotex, Inc.Cincinnati, OH

C. MackOwner

IHT Technology, Inc.New York, NY

Eva L. MaddoxPrincipalEva Maddox Branded EnvironmentChicago, IL

John M. MangThe Procter & Gamble CompanyKobe, Japan

John J. McDonough, M.D.Hand Surgery Specialists, Inc.Cincinnati, OH

38


47/62

Dane A. Miller, Ph.D.Warsaw, IN

Thomas E. MischellSenior Vice President, TaxesAmerican Financial Group, Inc.Cincinnati, OH

Joffre P. Moine IIExecutive Vice PresidentInfintech, LLCCincinnati, OH

William B. Monnig, MDPresidentThe Urology GroupEdgewood, KY

Valerie L. NewellCo-chairman & Managing DirectorRiverPoint Capital ManagementCincinnati, OH

Kirk L. PerryVP N. America Commercial Oper.Procter & Gamble Co.Cincinnati, OH

Melody Sawyer RichardsonDirector, Commercial Real EstateDivisionComey & Shepherd LLCCincinnati, OH

Yvonne C. RobertsonCommunity VolunteerCincinnati, OH

Alvin F. Roehr, Jr.

PresidentSchiff-Kreidler-ShellCincinnati, OH

George A. Schaefer, Jr.ChairmanFifth Third BancorpCincinnati, OH

James A. Schiff, PhDAssociate ProfessorUniversity of CincinnatiCincinnati, OH

Michael T. SchuelerPresidentHenkle-Schueler & Assoc.Lebanon, OH

James E. SchwabCincinnati Market President

US BankCincinnati, OH

Tony L. ShipleyChairmanQueen City AngelsCincinnati, OH

Frank T. ShumanPhiladelphia Turf Co. (Retired)Doylestown, PA

Peter J. Stern, MDChairman & ProfessorDept. of Orthopaedic SurgeryUC College of MedicineCincinnati, OH

Richard E. ThomburghVice ChairmanCorsair CapitalNew York, NY

Woodrow H. UibleManaging DirectorBartlett & Co.Cincinnati, OH

39


48/62

Myron E. Ullman IIIChairman & CEOJ. C. Penney Company, Inc.Piano, TX

Margaret K. ValentineVice President & SecretaryValentine Research, Inc.Cincinnati, OH

W. Thomas Van EttenSenior Vice President (Retired)Sun Trust BankOkatie, SC

Edward W. WedbushPresident & CEO

Wedbush Morgan Securities, Inc.Los Angeles, CA

Jeffrey P. WilliamsPresidentJeffrey Williams & Co. LLCNew York, NY

Steven A. WilsonPresident & CEO (Retired)VNU Advisory Services

Covington, KY

Frank C. Woodside 111, M.D.Dinsmore & ShohlCincinnati, OH

Wilbert L. ZieglerZiegler & Schneider, P.S.C.Covington, KY

Anthony Zingale

President & COO (Retired)Mercury InteractiveCupertino, CA

Trustees Emeriti

James E. BlakeneyDayton, OH

Clifford H. CoorsCincinnati, OH

'illiam H. DickhonerCincinnati, OH

Theodore H. Emmerich, Jr.Cincinnati, OH

Nancy R. Hamant, PhDCincinnati, OH

John H. HermaniesCincinnati, OH

Reuven J. Katz

Cincinnati, OH

James C. KautzTucson, AZ

David M. LanceCincinnati, OH

Jerome P. MontopoliBonita Springs, FL

Marjorie MotchCincinnati, OH

H. C. Buck NiehoffCincinnati, OH

S. Jay StewartChicago, IL

J. Clay StinnettCincinnati, OH

George L. StrikeCincinnati, OH

Jeffrey L. WylerCincinnati, OH

40


49/62

Honorary Trustees

Carl H. Lindner, Jr.Cincinnati, OH

Mrs. Louis NippertCincinnati, OH

Ex-Officio Trustees

Monica RimaiInterim PresidentUniversity of Cincinnati

Michael W. CarrollPresidentUniversity of Cincinnati Foundation

William E. HenrichAssociate Vice President &Chief Financial OfficerUniversity of Cincinnati Foundation

Louis D. BilionisDean, College of LawChairCouncil of DeansUniversity of Cincinnati

H. C. Buck NiehoffChairmanBoard of TrusteesUniversity of Cincinnati

Cora K. Ogle, PhDUC Faculty Representative toThe UC Foundation Board ofTrusteesUniversity of Cincinnati

Anthony J. PerzigianSenior Vice President for AcademicAffairs & ProvostUniversity of Cincinnati

Steven L. SimendingerPresidentUCAA Board of Governors

41


50/62

HOXWORTH BLOOD CENTERCOMMUNITY ADVISORY BOARD MEMBER LIST

Richard Aft, PhD 1-2012President, Philanthropic Leadership448 Warren AvenueCincinnati, Ohio 45220BUS: [email protected]

Lewis Assaley, PhD II - 2012Senior Vice PresidentMorgan Stanley221 East 4th StreetAtrium Two, 22nd FloorCincinnati, OH 45202BUS: [email protected]

William Becker, DO, MPH I-2009Medical and Technical AdvisoryCommittee, Vice-ChairMedical Director, Quest Diagnostic6700 Steger DriveCincinnati, OH 45237-3046BUS: 513-353-6237FAX: [email protected]

Brenita Brooks I -2011

Executive Director, Kidney Foundation220 Victory Parkway, #510Cincinnati, OH 45206BUS: 513-961-8105FAX: [email protected]

RobCraig 1-2010Taft, Stettinius and Hollister, LLP1717 Dixie Highway, Suite 340Covington, KY 41011

BUS: 859-331-2838FAX: [email protected]

Rob Davis 1-2012Senior Director, Program ManagementConvergys Corporation201 E. 4th Street 17.0130Cincinanti, Ohio 45202BUS: 513-723-6307FAX: [email protected]

BobDobbs 1-2011Vice President, Internal AuditAmerican Financial Group525 Vine St., 14th FloorCincinnati, OH 45202BUS: 513-369-5045FAX: 513-723-2760

[email protected]

Tim Egloff l - 2011Vice PresidentCommercial Banking9050 Centre Pointe DriveSuite 150West Chester, OH 45069BUS: 513-534-5280FAX: [email protected]

Dee Ellingwood 11-2011Senior Vice PresidentPlanning & Business DevelopmentCincinnati Children's Hospital3333 Burnet AvenueCincinnati, OH 45229BUS: 513-636-3667FAX: [email protected]

Andrew Filak, MDSr. Associate Dean, Academic AffairsE-870 Care/Crawley ML0555U C Academic Health CenterBUS: 513-558-7342FAX: [email protected]

Revised 9/09
mailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]


51/62


Camille Jones, MD, MPHAssistant Health CommissionerDepartment of Health3101 Burnet AvenueCincinnati, OH 45229-3098BUS: 513-357-7271FAX: 513-357-7290Camille.iones@cincinnati~oh.gov

Marianne Leininger II - 2009Blood Bank SupervisorMedical and Technical AdvisoryCommittee, Chair3131 Queen City AvenueCincinnati, OH 45238BUS: 513-389-5291FAX: [email protected]

Pamela J.Lowe 11-2012CELL: [email protected]

Sher McClanahan I - 2011Chief Operations OfficerBethesda North Hospital

10500 Montgomery RoadCincinnati, OH 45242BUS: 513-865-1221FAX: [email protected]

Colleen OToole, PhDPresidentGreater Cincinnati Health Council2100 Sherman Avenue, Suite 100Cincinnati, OH 45212-2775

BUS: 513-531-0200X107FAX: [email protected]

J. James Pearce, Jr. 1-2011PresidentPearce & Associates Consulting6528 Foxchase LaneCincinnati, OH 45243BUS: 513-708-8498FAX: [email protected]

Sara PellerAmerican Red CrossCincinnati Area Chapter720 SycamoreCincinnati, OH 45202-2185BUS: 513-579-3935

FAX: [email protected]

James D. PlummerVice President for FinanceUniversity of Cincinnati630 University PavilionML 0646BUS: 513-556-1299FAX: [email protected]

David R. Roettker 11-2011Certified Financial PlannerJohnson Investment Counsel, Inc.3777 West Fork RoadCincinnati, OH 45247BUS: 513-661-3100FAX: [email protected]

Reverend Fred Rowland 1-2010

Pastor, Metropolitan Baptist Church.1166 Hollywood AvenueCincinnati, OH 45244CELL: 513-300-7314HOME: [email protected]

Revised 9/09
mailto:Camille.iones@cincinnati~oh.govmailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:Camille.iones@cincinnati~oh.gov


52/62


Len Sauers, PhD, DABT II - 2010Vice President, Global SustainabilityThe Procter & Gamble CompanyTwo Procter & Gamble PlazaTN2-132Cincinnati, OH 45202-3315BUS: 513-983-4375FAX: [email protected]

James E. Schwab Ex-OfficioCincinnati Market PresidentUS Bank425 Walnut Street, CN-OH-W9Cincinnati, OH 45202BUS: 513-632-3298

CELL: [email protected]

Steve Seiter 11-2012Superintendent Corporate FacilitiesCintas Corporation6800 Cintas BoulevardMason, OH 45040BUS: 513-573-4036FAX: [email protected]

Dale J. Silver 11-2012Business Development DirectorVonLehman & Co., Inc.250 Grandview DriveFt. Mitchell, KY 41017BUS: 859-331-3300FAX: [email protected]

David Stern, MD

Vice President of Health AffairsUniversity of CincinnatiE-251 Medical Sciences BuildingCincinnati, OH 45267BUS: 513-558-7333FAX: [email protected]

Jeri Tolliver 1-2011Program Director, WDBZ1230 The Buzz1 Centennial Plaza, Suite 200705 Central AvenueCincinnati, OH 45202BUS: 513-749-1230FAX: [email protected]

Revised 9/09
mailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]


53/62

Inscho, Scott (Inschots)

From: phil HEIMLICH [[email protected]]Sent: Tuesday, November 03, 2009 10:07 AMTo: Inscho, Scott (inschots)Subject: RE: Passage of resolution

Sco t t ,

I assume that Deaconess will direct Johnson Investments to send the funds to you. Tony Woods

and Pat Ward mentioned there will be some agreement that will need to be signed between the

Heimlich Institute and Hoxworth. My father and I would definitely like to attend the event -

we'd appreciate your checking with us on the date before it is set.

Phil

Original Message

From: Inscho, Scott (inschots) fmailto:INSCHOTSfSUCMAIL.UC.EDUl

Sent: Monday, November 02, 2009 2:50 PM

To: "phil HEIMLICH'

Subject: RE: Passage of resolution

Phil,

Wow this is fantastic news! Thanks for all your help on this. We will be happy to speak to

Barbara Lohr from Deaconess about having an event at Hoxworth. Do you know the particulars in

terms of how the funds will be coming? I will contact her to see what kind of details are

involved with the event. I hope you and your father will be able to attend. I will let you

know how my conversation with her goes. Thanks, Scott

Original Message

From: phil HEIMLICH [mailto:PHEIMLICH(5)cinci.rr.com1

Sent: Friday, October 39, 2069 6:21 PM

To: Inscho, Scott (inschots)

Subject: Passage of resolution

Scott,

I'm pleased to inform you that the Heimlich Institute Board passed the following resolutions

today:

"After staff review and board discussion, it is moved that Deaconess Associations Foundation

commit Heimlich Institute funds as designated by Dr.

Henry Heimlich to the University of Cincinnati Foundation for the exclusive use of the

Hoxworth Blood Center for the following two research projects:

#1. A study to determine if t h e ^ ^ ^ ^ ^ ^ ^ ^ R e d a c t e d ^ ^ ^ ^ ^ ^ ^ ^ o r therapeuticintervention in the context of Bone Marrow failure associated with cancer therapy.

Amount of the request is $343,000

#2 A study to investigate cellular immunotherapy for viral diseases post transplant due

to delayed immune competence.

Amount of the request is $312,000"

The sense of the board members was that it would be appropriate to have some kind of event at

Hoxworth where the presentation of the grant could be made.

i
mailto:[email protected]:[email protected]:INSCHOTSfSUCMAIL.UC.EDUlmailto:PHEIMLICH(5)cinci.rr.com1mailto:PHEIMLICH(5)cinci.rr.com1mailto:INSCHOTSfSUCMAIL.UC.EDUlmailto:[email protected]


54/62

Barbara Lohr from Deaconess will likely be in touch with you about this.

Thank you and Dr. Sacher for your work in this matter.

Phil

2


55/62

Inscho, Scott (inschots)

From: Sacher, Ronald (sacherra)Sent: Friday, December 18, 2009 2:53 PMTo: Inscho, Scott (inschots)Cc: Bennison, Bernadette (bennisbg)Subject: RE: Heimlich Institute/Deaconess Associations Foundation Presentation

I t should come from me ,S co tt . We w i l l handle it s d i st r i b ut i on

Ronald A. Sacher, M.D.Prof esso r, I nt e r na l Medicine and Pathology Di re ct or , Hoxworth Blood Center Un iv er si ty ofC inc inn a t i Academic Hea lth Center 3130 High land Avenue PO Box 679055 C in c in n a t i , OH 45267-

6055Office: 513-558-1201

Fax: 513-558-1300

Ronald.SacherOuc.edu

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use

of the intended recipient(s) and may contain confidential and privileged information. Any

unauthorized review, use, disclosure or distribution is prohibited. If you are not theintended recipient, please contact the sender by reply e-mail and destroy all copies of the

original message.

Original Message

From: Inscho, Scott (inschots)

Sent: Friday, December 18, 2009 2:50 PM

To: Sacher, Ronald (sacherra)

Subject: Heimlich Institute/Deaconess Associations Foundation Presentation

Dr. Sacher,

Please see my draft email below inviting the CAB and SMT to this event. Please review and let

me know what you think. Should it come from you or me? Thanks, Scott

Dear Community Advisory

grant application & funding approval from Hoxworth Blood Center to the Heimlich Institute

Documents

Transcript of grant application & funding approval from Hoxworth Blood Center to the Heimlich Institute